Ran-IN-1
Based on 1 Customer Validation
Ran-IN-1 is a specific inhibitor of Ran GTPase. Ran-IN-1 selectively induces cytotoxicity and apoptosis in aneuploid ovarian cancer cells and also inhibits DNA repair. Ran-IN-1 exhibits antitumor activity and is useful for research on tumors such as epithelial ovarian cancer.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 2301869-11-2
- Formula: C27H26F3NO4S
- Molecular Weight:517.56
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Ran-IN-1 (Compound M36) (50-200 μM; 1 h) reduces Ran-GTP levels in TOV112D cells in a dose-dependent manner and increases Ran's thermal stability at a specific temperature[1].
Ran-IN-1 (0-40 μM) inhibits colony formation in TOV112D cells (IC50 = 10.02 ± 0.36 μM)[1].
Ran-IN-1 (40 μM; 96 h) suppresses the survival of aneuploid epithelial ovarian cancer (EOC) cells, such as TOV112D, TOV1949, and OV1946[1].
Ran-IN-1 (40 µM; 6 days) induces apoptosis in TOV112D cells, with no notable effect in ARPE cells[1].
Ran-IN-1 (20-50 μM) induces NR1D1 expression in aneuploid EOC cells (TOV112D and OV1946), increases levels of DNA damage markers, and suppresses the DDR pathway[1].
Ran-IN-1 (20 µM; 72 h) induces accumulation of DNA damage in TOV112D cells (increased p-γH2AX foci) and suppresses both homologous recombination (reduced Rad51 foci) and non-homologous end joining (reduced 53BP1 foci) pathways[1].
Ran-IN-1 (10-20 μM; 0-6 days) inhibits the homologous recombination pathway in epithelial ovarian cancer cell lines and exhibits synergistic effects with Olaparib (HY-10162)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TOV112D cells
-
Concentration:50, 100 and 150 μM
-
Incubation Time:1 h
-
Result:Reduced Ran-GTP levels in TOV112D cells in a dose-dependent manner.
-
Cell Line:TOV112D cells and ARPE cells
-
Concentration:40 µM
-
Incubation Time:6 days
-
Result:Increased the levels of cleaved PARP in TOV112D cells.
Did not affect the levels of cleaved PARP in ARPE cells.
Ran-IN-1 (200 mg/kg; intraperitoneal injection; single dose) achieves a plasma peak concentration of 100 µM at 30 minutes, remains at approximately 10 µM after 6 hours, and is still detectable after 24 hours in 6-week-old female CD1 mice, demonstrating acceptable pharmacokinetic properties[1].
Compound M36 (200 mg/kg; intraperitoneal injection; daily except weekends; 3 weeks) is well tolerated in 6-week-old female NRG mice, with no adverse effects on body weight gain[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NRG mice (6-week-old)[1]
-
Dosage:200 mg/kg
-
Administration:i.p.; daily; 32 days
-
Result:Significantly delayed tumor growth of this aggressive model and prolonged mouse survival.
Chemical Information
-
CAS No. 2301869-11-2
-
Appearance Solid
-
Molecular Weight 517.56
-
Formula C27H26F3NO4S
-
Color White to off-white
-
SMILES
FC1=CC=C(COC[C@@H]2[C@@H](OCC3=CC=C(F)C=C3)[C@@H](OCC4=CC=C(F)C=C4)[C@H](C(N)=S)O2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (193.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9321 mL | 9.6607 mL | 19.3214 mL | 48.3036 mL |
| 5 mM | 0.3864 mL | 1.9321 mL | 3.8643 mL | 9.6607 mL | |
| 10 mM | 0.1932 mL | 0.9661 mL | 1.9321 mL | 4.8304 mL | |
| 15 mM | 0.1288 mL | 0.6440 mL | 1.2881 mL | 3.2202 mL | |
| 20 mM | 0.0966 mL | 0.4830 mL | 0.9661 mL | 2.4152 mL | |
| 25 mM | 0.0773 mL | 0.3864 mL | 0.7729 mL | 1.9321 mL | |
| 30 mM | 0.0644 mL | 0.3220 mL | 0.6440 mL | 1.6101 mL | |
| 40 mM | 0.0483 mL | 0.2415 mL | 0.4830 mL | 1.2076 mL | |
| 50 mM | 0.0386 mL | 0.1932 mL | 0.3864 mL | 0.9661 mL | |
| 60 mM | 0.0322 mL | 0.1610 mL | 0.3220 mL | 0.8051 mL | |
| 80 mM | 0.0242 mL | 0.1208 mL | 0.2415 mL | 0.6038 mL | |
| 100 mM | 0.0193 mL | 0.0966 mL | 0.1932 mL | 0.4830 mL |